EGFR and glioblastoma: Its derivative, depatuxizumab mafodotin (Depatux-m) was tested in a phase III clinical trial versus placebo, showing increased PFS but no improvement in OS in newly diagnosed glioblastoma patients, with EGFR and corneal epitheliopathy occurring as an adverse effect in 94% of Depatux-m-treated patients [128].